Diagnosis and Management of Type I and Type V Hyperlipoproteinemia

DOI 8 Citations 34 References
  • Gotoda Takanari
    Department of Clinical and Molecular Epidemiology, 22nd Century Medical and Research Center, University of Tokyo Hospital.
  • Shirai Koji
    Internal Medicine, Sakura Hospital, School of Medicine, Toho University.
  • Ohta Takao
    Department of Child Health and Welfare (Pediatrics), Faculty of Medicine, University of the Ryukyus.
  • Kobayashi Junji
    Department of Lipidology, Kanazawa University Graduate School of Medical Science.
  • Yokoyama Shinji
    Department of Biochemistry, Nagoya City University Graduate School of Medical Sciences. Food and Nutritional Sciences, College of Biosciences and Biotechnology, Chubu University.
  • Oikawa Shinichi
    Division of Endocrinology and Metabolism, Department of Medicine, Nippon Medical School.
  • Bujo Hideaki
    Department of Genome Research and Clinical Application, Chiba University Graduate School of Medicine.
  • Ishibashi Shun
    Division of Endocrinology and Metabolism, Diabetes Center, Department of Medicine, Jichi Medical University Graduate School of Medicine.
  • Arai Hidenori
    Department of Human Health Sciences, Kyoto University Graduate School of Medicine.
  • Yamashita Shizuya
    Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine.
  • Harada-Shiba Mariko
    Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute.
  • Eto Masaaki
    School of Pharmaceutical Sciences, Ohu University and Department of Medicine, Ohu University Hospital.
  • Hayashi Toshio
    Department of Geriatrics, Nagoya University Graduate School of Medicine.
  • Sone Hirohito
    Department of Internal Medicine, University of Tsukuba Institute of Clinical Medicine.
  • Suzuki Hiroaki
    Department of Endocrinology and Metabolism, Graduate School of Comprehensive Human Sciences, University of Tsukuba.
  • Yamada Nobuhiro
    University of Tsukuba.

Bibliographic Information

Other Title
  • Research Committee for Primary Hyperlipidemia, Research on Measures against Intractable Diseases by the Ministry of Health, Labour and Welfare in Japan. Diagnosis and management of type I and type V hyperlipoproteinemia

Search this article

Abstract

Both type I and type V hyperlipoproteinemia are characterized by severe hypertriglyceridemia due to an increase in chylomicrons. Type I hyperlipoproteinemia is caused by a decisive abnormality of the lipoprotein lipase (LPL)- apolipoprotein C-II system, whereas the cause of type V hyperlipoproteinemia is more complicated and more closely related to acquired environmental factors. Since the relationship of hypertriglyceridemia with atherosclerosis is not as clear as that of hypercholesterolemia, and since type I and V hyperlipoproteinemia are relatively rare, few guidelines for their diagnosis and treatment have been established; however, type I and V hyperlipoproteinemia are clinically important as underlying disorders of acute pancreatitis, and appropriate management is necessary to prevent or treat such complications. Against such a background, here we propose guidelines primarily concerning the diagnosis and management of type I and V hyperlipoproteinemia in Japanese.

Journal

Citations (8)*help

See more

References(34)*help

See more

Related Projects

See more

Keywords

Details

Report a problem

Back to top